Physiological regulation of Akt activity and stability.

The serine/threonine protein kinase B (PKB, also known as Akt) constitutes an important node in diverse signaling cascades downstream of growth factor receptor tyrosine kinases. Akt plays an essential role in cell survival, growth, migration, proliferation, polarity, and metabolism (lipid and glucose); cell cycle progression; muscle and cardiomyocyte contractility; angiogenesis; and self-renewal of stem cells. Altered Akt activity has been associated with cancer and other disease conditions, such as diabetes mellitus, neurodegenerative diseases, and muscle hypotrophy. In the past decade, the upstream signals that lead to Akt activation, the downstream substrates that exert the effects of Akt, and the secondary binding proteins that regulate Akt activation have been well documented. Recent reports from our group and others have revealed how the stability of Akt protein is regulated through phosphorylation on its Thr-Pro motifs. This literature review details findings of those reports and others relevant to the regulation of Akt activation by its upstream kinases, with a focus on mammalian target of rapamycin complexes (mTORCs) and inactivation by PHLDA3 and the protein phosphatases PP2A and pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP). Reports on ubiquitin-dependent Akt degradation, caspase-dependent cleavage, and the roles of molecular chaperone heat shock protein 90 (Hsp90) in the regulation of Akt stability are summarized. The highlight will be on the role of "turn motif" phosphorylation and an isomerase, Pin1, in the regulation of Akt stability. We also discuss issues related to the intricate mTORC2-AktmTORC1 loop and the contradictory regulation of Akt phosphorylation and stabilization of Akt by mTORC2. Finally, we offer perspective on potential future directions for investigation, particularly on translating the knowledge we learned on the regulation of Akt stability into therapeutic intervention on human cancer with Akt alteration.

[1]  T. Roberts,et al.  Protein phosphatase 2A regulates life and death decisions via Akt in a context-dependent manner , 2007, Proceedings of the National Academy of Sciences.

[2]  M. Czech,et al.  A PP2A Regulatory Subunit Regulates C. elegans Insulin/IGF-1 Signaling by Modulating AKT-1 Phosphorylation , 2009, Cell.

[3]  D. Sternberg,et al.  Akt shows variable sensitivity to an Hsp90 inhibitor depending on cell context. , 2007, Experimental cell research.

[4]  E. Feldman,et al.  Insulin-like Growth Factor I Prevents Mannitol-induced Degradation of Focal Adhesion Kinase and Akt* , 2002, The Journal of Biological Chemistry.

[5]  J. Dixon,et al.  PTEN Protects p53 from Mdm2 and Sensitizes Cancer Cells to Chemotherapy* , 2002, The Journal of Biological Chemistry.

[6]  Toshiyuki Obata,et al.  Akt Enhances Mdm2-mediated Ubiquitination and Degradation of p53* , 2002, The Journal of Biological Chemistry.

[7]  A. Newton,et al.  PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. , 2007, Molecular cell.

[8]  W. Hahn,et al.  Involvement of PP2A in viral and cellular transformation , 2005, Oncogene.

[9]  J. Testa,et al.  Perturbations of the AKT signaling pathway in human cancer , 2005, Oncogene.

[10]  Frank McCormick,et al.  Akt activation by growth factors is a multiple-step process: the role of the PH domain , 1998, Oncogene.

[11]  Yonghong Xiao,et al.  GOLPH3 modulates mTOR signaling and rapamycin sensitivity in cancer , 2009, Nature.

[12]  T. Hunter,et al.  Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Jinxiang Zhang,et al.  PIN1 gene overexpression and β-catenin gene mutation/expression in hepatocellular carcinoma and their significance , 2007, Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban.

[14]  T. Tsuruo,et al.  Modulation of Akt kinase activity by binding to Hsp90. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Xiao Zhen Zhou,et al.  Function of WW domains as phosphoserine- or phosphothreonine-binding modules. , 1999, Science.

[16]  Yiling Lu,et al.  Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.

[17]  P. Tsichlis,et al.  AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. , 1999, Annual review of biochemistry.

[18]  P. Lenormand,et al.  Inhibition of B56-containing Protein Phosphatase 2As by the Early Response Gene IEX-1 Leads to Control of Akt Activity* , 2007, Journal of Biological Chemistry.

[19]  X. Zhou,et al.  Peptidyl-prolyl cis/trans isomerase Pin1 is critical for the regulation of PKB/Akt stability and activation phosphorylation , 2009, Oncogene.

[20]  Shiwen Zhang,et al.  Kinetic Mechanism of AKT/PKB Enzyme Family* , 2006, Journal of Biological Chemistry.

[21]  E. Kandel,et al.  The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. , 1999, Experimental cell research.

[22]  Tsutomu Ohta,et al.  PH Domain-Only Protein PHLDA3 Is a p53-Regulated Repressor of Akt , 2009, Cell.

[23]  N. Hay,et al.  The two TORCs and Akt. , 2007, Developmental cell.

[24]  D. Woods,et al.  Phosphorylation of HDM2 by Akt , 2002, Oncogene.

[25]  Wolfgang Link,et al.  The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. , 2008, Current cancer drug targets.

[26]  H Nojima,et al.  A truncated isoform of the PP2A B56 subunit promotes cell motility through paxillin phosphorylation , 2000, The EMBO journal.

[27]  A. Jahani-Asl,et al.  Caspase‐3‐mediated cleavage of Akt: Involvement of non‐consensus sites and influence of phosphorylation , 2007, FEBS letters.

[28]  A. Merlo,et al.  Stabilization of Mdm2 via Decreased Ubiquitination Is Mediated by Protein Kinase B/Akt-dependent Phosphorylation* , 2004, Journal of Biological Chemistry.

[29]  S. Shenolikar,et al.  From promiscuity to precision: protein phosphatases get a makeover. , 2009, Molecular cell.

[30]  M. Spinella,et al.  A p53-dominant transcriptional response to cisplatin in testicular germ cell tumor-derived human embyronal carcinoma , 2005, Oncogene.

[31]  G. Mills,et al.  A new mutational AKTivation in the PI3K pathway. , 2007, Cancer cell.

[32]  E. Medina,et al.  Tumor necrosis factor-{alpha} decreases Akt protein levels in 3T3-L1 adipocytes via the caspase-dependent ubiquitination of Akt. , 2005, Endocrinology.

[33]  R. Memmott,et al.  Akt-dependent and -independent mechanisms of mTOR regulation in cancer. , 2009, Cellular signalling.

[34]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[35]  A. Tsimokha,et al.  Role of proteasomes in cellular regulation. , 2008, International review of cell and molecular biology.

[36]  A. Ryo,et al.  Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. , 2003, Molecular cell.

[37]  L. Cantley,et al.  PI3K pathway alterations in cancer: variations on a theme , 2008, Oncogene.

[38]  B. Hemmings,et al.  PKB Binding Proteins Getting in on the Akt , 2002, Cell.

[39]  P. Ruvolo.  Ceramide regulates cellular homeostasis via diverse stress signaling pathways , 2001, Leukemia.

[40]  David M Sabatini,et al.  An expanding role for mTOR in cancer. , 2005, Trends in molecular medicine.

[41]  Elisabeth S Yeh,et al.  PIN1, the cell cycle and cancer , 2007, Nature Reviews Cancer.

[42]  Ming Tan,et al.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.

[43]  A. Schönthal,et al.  Role of serine/threonine protein phosphatase 2A in cancer. , 2001, Cancer letters.

[44]  J. Bayascas,et al.  Dissecting the role of the 3-phosphoinositide-dependent protein kinase-1 (PDK1) signalling pathways , 2008, Cell cycle.

[45]  R. Meller,et al.  Ubiquitin-proteasome system as a modulator of cell fate. , 2008, Current opinion in pharmacology.

[46]  L. Pirola,et al.  Isoform-specific defects of insulin stimulation of Akt/protein kinase B (PKB) in skeletal muscle cells from type 2 diabetic patients , 2008, Diabetologia.

[47]  J. Yates,et al.  Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. , 2007, Nature.

[48]  Tilman Grune,et al.  The proteasomal system. , 2009, Molecular aspects of medicine.

[49]  Joseph R. Nevins,et al.  A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells , 2004, Nature Cell Biology.

[50]  Yow-Ming C Wang,et al.  c-Jun N-Terminal Kinases Mediate Reactivation of Akt and Cardiomyocyte Survival After Hypoxic Injury In Vitro and In Vivo , 2005, Circulation research.

[51]  Q. Wei,et al.  Recent progress on the structure of Ser/Thr protein phosphatases , 2008, Science in China Series C: Life Sciences.

[52]  K. Lu.  Prolyl isomerase Pin1 as a molecular target for cancer diagnostics and therapeutics. , 2003, Cancer cell.

[53]  G. Georgakis,et al.  Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond. , 2005, Future oncology.

[54]  Jacob D. Jaffe,et al.  mSin1 Is Necessary for Akt/PKB Phosphorylation, and Its Isoforms Define Three Distinct mTORC2s , 2006, Current Biology.

[55]  S. Cohen,et al.  Re-evaluating AKT regulation: role of TOR complex 2 in tissue growth. , 2007, Genes & development.

[56]  G. Georgakis,et al.  The heat shock protein 90 inhibitor 17‐AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9 , 2006, British journal of haematology.

[57]  Yigong Shi.  Assembly and structure of protein phosphatase 2A , 2009, Science in China Series C: Life Sciences.

[58]  Yong Liao,et al.  HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation , 2001, Nature Cell Biology.

[59]  L. Neckers,et al.  Geldanamycin as a Potential Anti-Cancer Agent: Its Molecular Target and Biochemical Activity , 2004, Investigational New Drugs.

[60]  M. Mumby.  PP2A: Unveiling a Reluctant Tumor Suppressor , 2007, Cell.

[61]  G. Morgan,et al.  Untangling the unfolded protein response , 2008, Cell cycle.

[62]  F. Tsai,et al.  Mutation analysis of the tumor suppressor gene PPP2R1B in human cervical cancer. , 2007, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[63]  Yizheng Wang,et al.  Requirement of dendritic Akt degradation by the ubiquitin–proteasome system for neuronal polarity , 2006, The Journal of cell biology.

[64]  P. Vogt,et al.  PI 3-kinase and cancer: changing accents. , 2009, Current opinion in genetics & development.

[65]  D. Goberdhan,et al.  mTOR: dissecting regulation and mechanism of action to understand human disease. , 2009, Biochemical Society transactions.

[66]  Ling Yan,et al.  Phosphatases and regulation of cell death. , 2008, Methods in enzymology.

[67]  J. Qin,et al.  SIN1/MIP1 Maintains rictor-mTOR Complex Integrity and Regulates Akt Phosphorylation and Substrate Specificity , 2006, Cell.

[68]  P. Tsichlis,et al.  Regulation of the Akt kinase by interacting proteins , 2005, Oncogene.

[69]  J. Testa,et al.  Activation of AKT kinases in cancer: implications for therapeutic targeting. , 2005, Advances in cancer research.

[70]  J. Sowadski,et al.  Prevalent overexpression of prolyl isomerase Pin1 in human cancers. , 2004, The American journal of pathology.

[71]  D. V. van Aalten,et al.  PDK1, the master regulator of AGC kinase signal transduction. , 2004, Seminars in cell & developmental biology.

[72]  J. Woodgett,et al.  Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. , 1998, The Biochemical journal.

[73]  T. Hagen,et al.  Age-associated impairment of Akt phosphorylation in primary rat hepatocytes is remediated by alpha-lipoic acid through PI3 kinase, PTEN, and PP2A , 2009, Biogerontology.

[74]  W. Kong,et al.  Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. , 2008, Current cancer drug targets.

[75]  R. Bernards,et al.  Protein phosphatase 2A regulatory subunits and cancer. , 2009, Biochimica et biophysica acta.

[76]  L. Neckers,et al.  Heat shock protein 90 , 2003, Current opinion in oncology.

[77]  Xiaoyuan Chen,et al.  From protein-protein interaction to therapy response: molecular imaging of heat shock proteins. , 2009, European journal of radiology.

[78]  Tao Zhang,et al.  New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. , 2009, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[79]  L. Neckers.  Chaperoning oncogenes: Hsp90 as a target of geldanamycin. , 2006, Handbook of experimental pharmacology.

[80]  C. Widmann,et al.  Caspase-dependent Cleavage of Signaling Proteins during Apoptosis , 1998, The Journal of Biological Chemistry.

[81]  D. Sabatini,et al.  DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival , 2009, Cell.

[82]  A. Newton,et al.  Cellular Signaling Pivoting around PDK-1 , 2000, Cell.

[83]  B. Manning,et al.  A complex interplay between Akt, TSC2 and the two mTOR complexes. , 2009, Biochemical Society transactions.

[84]  W. Lee,et al.  Regulation of Phosphorylation of Thr-308 of Akt, Cell Proliferation, and Survival by the B55α Regulatory Subunit Targeting of the Protein Phosphatase 2A Holoenzyme to Akt* , 2008, Journal of Biological Chemistry.

[85]  L. Cantley,et al.  Targeting the PI3K-Akt pathway in human cancer: rationale and promise. , 2003, Cancer cell.

[86]  J. Olefsky,et al.  Protein Phosphatase 2A Negatively Regulates Insulin's Metabolic Signaling Pathway by Inhibiting Akt (Protein Kinase B) Activity in 3T3-L1 Adipocytes , 2004, Molecular and Cellular Biology.

[87]  K. Bhalla,et al.  Targeting HSP90 for cancer therapy , 2009, British Journal of Cancer.

[88]  Moshe Oren,et al.  Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis , 2002, Oncogene.

[89]  Moshe Oren,et al.  Regulation of p53: intricate loops and delicate balances. , 2002, Biochemical pharmacology.

[90]  D. Guertin,et al.  Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. , 2006, Developmental cell.

[91]  J. Peyrat,et al.  Recent advances in Hsp90 inhibitors as antitumor agents. , 2008, Anti-cancer agents in medicinal chemistry.

[92]  Xiao Zhen Zhou,et al.  Targeting carcinogenesis: A role for the prolyl isomerase Pin1? , 2006, Molecular carcinogenesis.

[93]  T. Tsuruo,et al.  Cleavage and inactivation of antiapoptotic Akt/PKB by caspases during apoptosis , 2000, Journal of cellular physiology.

[94]  Jung Young Lee,et al.  Mutational Analysis of AKT1, AKT2 and AKT3 Genes in Common Human Carcinomas , 2006, Oncology.

[95]  D. Barford,et al.  Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. , 2002, Molecular cell.

[96]  J. Ostrander,et al.  Regulated Association of Protein Kinase B/Akt with Breast Tumor Kinase* , 2005, Journal of Biological Chemistry.

[97]  A. Newton,et al.  Common Polymorphism in the Phosphatase PHLPP2 Results in Reduced Regulation of Akt and Protein Kinase C* , 2009, Journal of Biological Chemistry.

[98]  M. Hung,et al.  Induction of Akt activity by chemotherapy confers acquired resistance. , 2009, Journal of the Formosan Medical Association = Taiwan yi zhi.

[99]  A. Newton,et al.  Lipid activation of protein kinases This work was supported in part by National Institutes of Health GM43154. Published, JLR Papers in Press, November 24, 2008. , 2009, Journal of Lipid Research.

[100]  L. Lerman,et al.  Ubiquitin and ubiquitin-like proteins in protein regulation. , 2007, Circulation research.

[101]  W. Liu,et al.  Protein phosphatase 2A-linked and -unlinked caspase-dependent pathways for downregulation of Akt kinase triggered by 4-hydroxynonenal , 2003, Cell Death and Differentiation.

[102]  N. Hay,et al.  Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner. , 2006, Cancer cell.

[103]  A. Newton,et al.  The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C , 2008, The EMBO journal.

[104]  G. Mills,et al.  XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. , 2001, Cancer research.

[105]  M. Hung,et al.  Novel targets of Akt, p21(Cipl/WAF1), and MDM2. , 2002, Seminars in oncology.

[106]  K. Inoki,et al.  Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling , 2008, The EMBO journal.

[107]  J. Woodgett,et al.  Unravelling the activation mechanisms of protein kinase B/Akt , 2003, FEBS letters.

[108]  Enrique Casado,et al.  PI3K/Akt signalling pathway and cancer. , 2004, Cancer treatment reviews.

[109]  A. Tee,et al.  Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms. , 2009, Cellular signalling.

[110]  P. Pandolfi,et al.  Regulation of the p73 protein stability and degradation. , 2005, Biochemical and biophysical research communications.

[111]  J. Woo,et al.  Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. , 2006, Developmental cell.

[112]  Huong T. T. Pham,et al.  Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the Aβ subunit gene , 2001, Oncogene.

[113]  P. Vogt,et al.  Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[114]  B. Hemmings,et al.  PIKKing on PKB: regulation of PKB activity by phosphorylation. , 2009, Current opinion in cell biology.

[115]  A. Newton,et al.  Spatiotemporal dynamics of lipid signaling: Protein kinase C as a paradigm , 2008, IUBMB life.

[116]  B. Hemmings,et al.  Physiological functions of protein kinase B/Akt. , 2004, Biochemical Society transactions.

[117]  L. Neckers,et al.  Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics – an update , 2005, Expert opinion on emerging drugs.

[118]  J. Testa,et al.  Mapping of AKT3, encoding a member of the Akt/protein kinase B family, to human and rodent chromosomes by fluorescence in situ hybridization , 2000, Cytogenetic and Genome Research.

[119]  Huong T. T. Pham,et al.  Disruption of protein phosphatase 2A subunit interaction in human cancers with mutations in the Aα subunit gene , 2001, Oncogene.

[120]  W. Hahn,et al.  Multiple pathways regulated by the tumor suppressor PP2A in transformation. , 2008, Trends in molecular medicine.

[121]  A. Newton,et al.  The life and death of protein kinase C. , 2008, Current drug targets.

[122]  J. Blenis,et al.  PHLPPing it off: phosphatases get in the Akt. , 2007, Molecular cell.

[123]  A. Newton,et al.  PHLiPPing the switch on Akt and protein kinase C signaling , 2008, Trends in Endocrinology & Metabolism.

[124]  N. Hay,et al.  The Akt-mTOR tango and its relevance to cancer. , 2005, Cancer cell.

[125]  J. Bos.  A target for phosphoinositide 3-kinase: Akt/PKB. , 1995, Trends in biochemical sciences.

[126]  Tak W. Mak,et al.  Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis , 2006, Nature Reviews Cancer.

[127]  K. Inoki,et al.  Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. , 2006, Genes & development.

[128]  A. Newton,et al.  Regulation of the ABC kinases by phosphorylation: protein kinase C as a paradigm. , 2003, The Biochemical journal.

[129]  D. Sabatini,et al.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. , 2006, Molecular cell.

[130]  J. Testa,et al.  AKT signaling in normal and malignant cells , 2005, Oncogene.

[131]  V. Janssens,et al.  PP2A holoenzyme assembly: in cauda venenum (the sting is in the tail). , 2008, Trends in biochemical sciences.

[132]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[133]  O. Riesterer,et al.  Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells , 2004, Oncogene.

[134]  Xiao Zhen Zhou,et al.  The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease , 2007, Nature Reviews Molecular Cell Biology.

[135]  A. Ryo,et al.  Prolyl isomerase Pin1: a catalyst for oncogenesis and a potential therapeutic target in cancer , 2003, Journal of Cell Science.

[136]  D. Sabatini.  mTOR and cancer: insights into a complex relationship , 2006, Nature Reviews Cancer.

[137]  L. Mayo,et al.  A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[138]  B. Hemmings,et al.  Structure, regulation and function of PKB/AKT--a major therapeutic target. , 2004, Biochimica et biophysica acta.

[139]  K. Guan,et al.  Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? , 2006, Oncogene.

[140]  K. Lu,et al.  Phosphorylation-specific prolyl isomerization: is there an underlying theme? , 2005, Nature Cell Biology.

[141]  R. Shin,et al.  Prolyl isomerase, Pin1: new findings of post-translational modifications and physiological substrates in cancer, asthma and Alzheimer’s disease , 2008, Cellular and Molecular Life Sciences.

[142]  P. Jagadeeswaran,et al.  Microarray analysis of prothrombin knockdown in zebrafish. , 2009, Blood cells, molecules & diseases.

[143]  A. Newton,et al.  The Phosphatase PHLPP Controls the Cellular Levels of Protein Kinase C* , 2008, Journal of Biological Chemistry.

[144]  W. Hahn,et al.  Cancer-associated PP2A Aalpha subunits induce functional haploinsufficiency and tumorigenicity. , 2005, Cancer research.

[145]  Yoshihiro Kakeji,et al.  Deregulation of the Akt pathway in human cancer. , 2008, Current cancer drug targets.

[146]  J. Pipas,et al.  SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation , 2005, Oncogene.

[147]  Jason A. Koutcher,et al.  Identification of a tumour suppressor network opposing nuclear Akt function , 2006, Nature.

[148]  M. Hung,et al.  Advances in Brief A New Role of Protein Phosphatase 2 A in Adenoviral E 1 A Protein-Mediated Sensitization to Anticancer Drug-Induced Apoptosis in Human Breast Cancer Cells , 2004 .

[149]  K. Lu.  Pinning down cell signaling, cancer and Alzheimer's disease. , 2004, Trends in biochemical sciences.

[150]  Small‐Molecule Inhibitors of PDK1 , 2008, ChemMedChem.

[151]  P. Workman,et al.  Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. , 2006, Endocrine-related cancer.

[152]  E. Karapanagiotou,et al.  Heat shock protein inhibitors and vaccines as new agents in cancer treatment. , 2009, Expert opinion on investigational drugs.

[153]  Dan Liu,et al.  The Role of Asp-462 in Regulating Akt Activity* , 2002, The Journal of Biological Chemistry.

[154]  Lewis C Cantley,et al.  The phosphoinositide 3-kinase pathway. , 2002, Science.

[155]  D. Alessi,et al.  Identification of Protor as a novel Rictor-binding component of mTOR complex-2. , 2007, The Biochemical journal.

[156]  J. Schlessinger,et al.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[157]  D. Alessi,et al.  mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). , 2008, The Biochemical journal.

[158]  D. Pim,et al.  Activation of the protein kinase B pathway by the HPV-16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A , 2005, Oncogene.

[159]  V. Giguère,et al.  Phosphatases at the heart of FoxO metabolic control. , 2008, Cell metabolism.

[160]  W. Hahn,et al.  Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. , 2003, Cancer cell.

[161]  C. van Hoof,et al.  PP2A: the expected tumor suppressor. , 2005, Current opinion in genetics & development.

[162]  Gerard Manning,et al.  TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. , 2009, Cancer research.

[163]  P. Tsichlis,et al.  PDK2: A Complex Tail in One Akt , 2001, Science's STKE.

[164]  W. Muller,et al.  The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer , 2007, Oncogene.

[165]  F. Fuller-Pace,et al.  A novel site of AKT‐mediated phosphorylation in the human MDM2 onco‐protein , 2004, FEBS letters.

[166]  E. Karapanagiotou,et al.  The role of mTOR in the management of solid tumors: an overview. , 2009, Cancer treatment reviews.

[167]  P. Cohen,et al.  Mechanism of activation of protein kinase B by insulin and IGF‐1. , 1996, The EMBO journal.

[168]  T. Tsuruo,et al.  The Cleavage of Akt/Protein Kinase B by Death Receptor Signaling Is an Important Event in Detachment-induced Apoptosis* , 2001, The Journal of Biological Chemistry.

[169]  S. Volinia,et al.  The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults , 2002, Nature.

[170]  mTORC2 Caught in a SINful Akt. , 2006, Developmental cell.

[171]  T. Hunter,et al.  Protein Phosphatase 2A Antagonizes ATM and ATR in a Cdk2- and Cdc7-Independent DNA Damage Checkpoint , 2006, Molecular and Cellular Biology.

[172]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[173]  M. Amolins,et al.  Natural product inhibitors of Hsp90: potential leads for drug discovery. , 2009, Mini reviews in medicinal chemistry.

[174]  A. Newton,et al.  PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. , 2005, Molecular cell.

[175]  T. Hunter,et al.  Oncogenic kinase signalling , 2001, Nature.

[176]  J. Minna,et al.  Alterations of the PPP2R1B gene in human lung and colon cancer. , 1998, Science.

[177]  A. Lièvre,et al.  Mutations and Response to Epidermal Growth Factor Receptor Inhibitors , 2009, Clinical Cancer Research.

[178]  Z. Winters,et al.  Activated Akt expression in breast cancer: correlation with p53, Hdm2 and patient outcome. , 2005, European journal of cancer.

[179]  Spyro Mousses,et al.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.

[180]  R. Ruediger,et al.  Domains Necessary for Gα12 Binding and Stimulation of Protein Phosphatase-2A (PP2A): Is Gα12 a Novel Regulatory Subunit of PP2A? , 2007, Molecular Pharmacology.

[181]  Clive Wilson,et al.  The protein phosphatase PP2A-B′ subunit Widerborst is a negative regulator of cytoplasmic activated Akt and lipid metabolism in Drosophila , 2008, Journal of Cell Science.

[182]  D. Alessi,et al.  New Insights into mTOR Signaling: mTORC2 and Beyond , 2009, Science Signaling.

[183]  L. Neckers,et al.  Heat shock protein 90 as a molecular target for cancer therapeutics. , 2003, Cancer cell.

[184]  R. Hresko,et al.  mTOR·RICTOR Is the Ser473 Kinase for Akt/Protein Kinase B in 3T3-L1 Adipocytes* , 2005, Journal of Biological Chemistry.

[185]  G. Russo,et al.  Low frequency of alterations of the α (PPP2R1A) and β (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms , 2000, Oncogene.

[186]  L. Neckers,et al.  Hsp90 inhibitors as novel cancer chemotherapeutic agents. , 2002, Trends in molecular medicine.

[187]  Li Zhao,et al.  Oncogenic PI3K deregulates transcription and translation , 2005, Nature Reviews Cancer.

[188]  B. Hemmings,et al.  Physiological roles of PKB/Akt isoforms in development and disease. , 2007, Biochemical Society transactions.

[189]  Claudio R. Santos,et al.  A new player in the orchestra of cell growth: SREBP activity is regulated by mTORC1 and contributes to the regulation of cell and organ size. , 2009, Biochemical Society transactions.

[190]  W. Hahn,et al.  SV40 small T antigen and PP2A phosphatase in cell transformation , 2008, Cancer and Metastasis Reviews.